Loading…
Pre-Approval Information Exchange Act of 2022
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
43pct
1d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Pre-Approval Information Exchange Act of 2022 This bill specifies that product information that is exchanged between drug manufacturers and certain health care entities (e.g., formulary committees) about drug products before regulatory approval is not considered to be misbranding if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2022 · fourth_quarter · Pharmacy
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. HR 7008/HR 7667/HR 9297/HR 2617 S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S. 3791/HR 7051 - Access to Prescription Digital Therapeutics Act of 2022 - to create a benefit category in Medicare and Medicaid for prescription digital therapeutics HR 7213 - Equitable Community Access to Pharmacy Services Act of 2022 - to reimburse certain COVID-19 care services provided by pharmacists under Medicare Part B
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Medicare/Medicaid
Pre-approval information exchange - lobbying for the introduction of a bill to codify FDA guidance creating a safe harbor for the practice of pre-approval information exchange between drug manufacturers and health plans. HR 7008/HR 7667/HR 9297/HR 2617 S.1909/HR. 3554 - A bill relating to direct and indirect remuneration in Medicare Part D. S. 1362 - Pharmacy and Medically Underserved Areas Enhancement Act - to provide for coverage under the Medicare program of pharmacist services S. 3791/HR 7051 - Access to Prescription Digital Therapeutics Act of 2022 - to create a benefit category in Medicare and Medicaid for prescription digital therapeutics HR 7213 - Equitable Community Access to Pharmacy Services Act of 2022 - to reimburse certain COVID-19 care services provided by pharmacists under Medicare Part B
Client expense: $90,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Republican |
| TX |
| Scott H. Peters | Democratic | CA |